| Name | Title | Contact Details |
|---|
Changing how we grow with plant cell cultures.
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.
Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.
Co-Founded by world-renowned mycologist Paul Stamets, MycoMedica, PBC is a life sciences company developing therapeutic drugs derived from fungi to help people live healthier, better lives.